Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.
about
Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Outcomes of re-treatment with ...... prospective multicenter study.
@en
Outcomes of re-treatment with ...... c breast cancer patients after
@nl
type
label
Outcomes of re-treatment with ...... prospective multicenter study.
@en
Outcomes of re-treatment with ...... c breast cancer patients after
@nl
prefLabel
Outcomes of re-treatment with ...... prospective multicenter study.
@en
Outcomes of re-treatment with ...... c breast cancer patients after
@nl
P2093
P2860
P356
P1433
P1476
Outcomes of re-treatment with ...... prospective multicenter study.
@en
P2093
Donggeng Liu
Hong Zheng
Qingyuan Zhang
Rongcheng Luo
Shiying Yu
Xiaojia Wang
P2860
P304
50643-50655
P356
10.18632/ONCOTARGET.9331
P407
P577
2016-05-27T00:00:00Z